Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis

Objectives: Oxidative stress is an important pathophysiological mechanism in non-alcoholic steatohepatitis (NASH). We aimed to evaluate serum xanthine oxidase (XO) (as a generator of reactive oxygen species), superoxide dismutase (SOD), glutathione peroxidase (GSHPx), paraoxonase (PON1) activities, nitric oxide (NO) and thiol levels in patients with NASH

Serum paraoxonase 1 activity and malondialdehyde levels in patients with ulcerative colitis

This study was designed to evaluate the oxidative and antioxidative status in patients with ulcerative colitis by detecting antioxidant enzyme paraoxonase I activity together with the level of a well-known marker of oxidative stress, malondialdehvde. Serum paraoxonase 1 activity and malondialdehyde levels were analysed in 30 patients with ulcerative colitis and 30 controls using a spectrophotometric method; correlation analysis was made between these variables. Serum malondialdehyde levels were higher in the ulcerative colitis group (median: 2.5, range: 0.5-9.4 nmol ml(-1)) than among the controls (median:1.1. range: 0.5-2.3 nmol/ml(-1); p < 0.001) whereas paraoxonase I activities were lower in the ulcerative colitis group (median: 158.4, range: 61.6 -264.1Ul(-1)) than in the control group (median: 233.3, range: 114.4-431.0 Ul(-1); p < 0.001). There was no correlation between serum malondialdehyde level, paraoxonase 1 activity and disease activity. (1) Increased reactive oxygen metabolites levels in ulcerative colitis may result in a pro-oxidation environment, which in turn could result in decreased antioxidant paraoxonase 1 activity and increased malondialdehyde levels, (2) increased cytokines may be a possible cause of decreased paraoxonase 1 activity and (3) decreased serum paraoxonase 1 activity may be a part of an inflammatory response. Copyright (c) 2005 John Wiley & Sons, Ltd

Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients

The goal of this study is to establish whether 5 days of ceftriaxone treatment was sufficient to cure culture-negative neutrocytic ascites in cirrhotic patients. We studied 50 cirrhotic patients with culture-negative neutrocytic ascites. All were treated with ceftriaxone, 1.0 g IV, twice a day for 5 days. A control paracentesis was performed 48 hours after starting the therapy to assess response to the treatment. A total of 17 demographic, clinical, and laboratory variables were recorded in all cases on the day of diagnosis of CNNA. The mean age of the patients was 57.7 +/- 13.2 years. Thirty-two patients were males and 18 females. The etiology of cirrhosis was hepatitis C virus in 20 patients (40%), hepatitis B virus in 16 patients (32%), cryptogenic in 13 patients (26%), and alcohol abuse in I patient (2%). Eighty percent of the patients were in Child-Pugh Class C. Resolution rate of culture-negative neutrocytic ascites on day 5 of treatment was 78%. Hospital mortality in cirrhotic patients with culture negative neutrocytic ascites was 4%. Statistical analysis showed that none of the 13 selected variables as covariates significantly related with the resolution of culture-negative neutrocytic ascites. Five days of ceftriaxone treatment is an adequate therapy for culture-negative neutrocytic ascites

The role of serum zinc and other factors on the prevalence of muscle cramps in non-alcoholic cirrhotic patients

Background/Aims: To determine the prevalence of muscle cramps in patients with liver cirrhosis and to identify factors associated with their development, especially serum zinc

Serum paraoxonase activity is decreased in the active stage of Behcet's disease

Aims: To evaluate paraoxonase1 (PON1) activities and malondialdehyde (MDA) levels, one of the end products of lipid peroxidation induced by reactive oxygen species in patients with Behcet's disease (BD) in the active stage

Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment

The present study was designed to investigate the relationship between the serum levels of oxidant-antioxidant system (malondialdehyde (MDA) level, Paraoxonase (PON1) activity, nitric oxide (NO) level and superoxide dismutase (SOD) activity) and thyroid hormone status in hypothyroidism pre and posttreatment. The study group comprised 33 patients with primary hypothyoidism. 18 of these patients were reevaluated after euthyroid state i.e. at least 6 months of thyroxine replacement. The patients were compared with 26 normal healthy controls. Serum MDA level, PON1 activity, NO level and SOD activity were measured according to an enzymatic spectrophotometric method. MDA levels were found higher in patients with hypothyroidism before the treatment than the controls. MDA levels were also found to be decreased after the treatment in patients with hyothyroidism. However MDA were found still higher than the controls after the treatment. PON1 activity was found to be lower in patients pretreatment when compared to posttreatment hypothyroidism and controls. Posttreatment of hypothyroidism mean PON1 activity significantly increased compared to pretreatment level but it was still significantly lower than control level. NO level was higher in pretreatment hypothyroidism when compared to controls. SOD activity was not found different in patients before treatment when compared to controls. SOD activity was significantly higher in after treatment when compared to both pretreatment and control levels. In conclusion, increased ROS levels in hypothyroidism may result in a pro-oxidation environment, which in turn could result in decreased antioxidant PON1 activity, increased MDA and NO levels. As a result, lipid peroxidation may have a role in the pathogenesis of the atherosclerosis in hypothyroidism

Advanced oxidation protein products, total thiol levels and total oxidant/antioxidant status in patients with nash

Background/Aims: In this study we aim to evaluate the relationship of advanced oxidation protein products (AOPP), total thiol, total antioxidant status (TAS), total oxidant status (TOS) levels and oxidative stress index (OSI) in patients with nonalcoholic steatohepatitis (NASH)

Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis

Objectives: We aimed to evaluate antioxidant paraoxonase 1 activity together with malondialdehyde (NIDA) (an oxidative stress parameter) levels in patients with rheumatoid arthritis

Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis

We aimed to determine the importance of neutrophil activation and the source of oxidative stress in the pathogenesis of rheumatoid arthritis (RA) by quantification of advanced oxidation protein products (AOPP) and total thiol levels as markers of oxidative protein damage, malondialdehyde (MDA) levels as a marker of lipid peroxidation and myeloperoxidase (MPO) activity as a marker of neutrophil activation in patients with RA. Fifty-seven rheumatoid arthritis patients were included in the study and sub-grouped according to disease activity (active, n = 31; inactive, n = 26) and compared with healthy controls (n = 25). Serum MPO activity, AOPP, MDA, and thiol levels were measured by an enzymic spectrophotometric method. Serum MPO activity (p < 0.001), AOPP (p < 0.001), MDA (p < 0.001) and levels of thiol (p < 0.002), were higher in the patient group than the controls. Active and inactive RA groups were compared with the control group and there were significant differences between each parameter. MPO activity, AOPP, MDA and thiol levels were significantly higher in both active and inactive RA patients than the controls. On the other hand, when a comparison was made between active and the inactive stage, a statistically significant difference was present only in MDA (p < 0.05) and AOPP levels (p < 0.05). There was also a significant positive correlation between all parameters. These data strongly suggest that neutrophils, which constitute the most important source of chlorinated oxidants due to their high MPO content, may be involved in serum AOPP formation and therefore the production of a novel class of pro-inflammatory mediators of oxidative stress in RA patients and that protein oxidation could play an important role in the pathogenesis of RA as does lipid peroxidation.PMID: 16142689 [PubMed - indexed for MEDLINE]Publication Types, MeSH Terms, SubstancesLinkOut - more resourcesSupplemental ContentSave itemsAdd to FavoritesView more optionsRelated citations in PubMedIncreased advanced oxidation protein products in Behçet's disease: a new activity marker?[Br J Dermatol. 2004]Protein oxidation status in patients with ankylosing spondylitis.[Rheumatology (Oxford). 2004]Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis.[Clin Biochem. 2005]Review Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions.[Nephrol Dial Transplant. 1996]Review Are advanced oxidation protein products potential uremic toxins?[Kidney Int Suppl. 2003][Br J Dermatol. 2004]Protein oxidation status in patients with ankylosing spondylitis.[Rheumatology (Oxford). 2004]Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis.[Clin Biochem. 2005]Review Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions.[Nephrol Dial Transplant. 1996]Review Are advanced oxidation protein products potential uremic toxins?[Kidney Int Suppl. 2003

Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration

Our objective was to investigate antioxidant paraoxonase 1 (PON1) activity together with malondialdehyde (MDA) levels to evaluate oxidative stress in patients with age-related macular degeneration (AMD), an important cause of blindness in the elderly population. Serum PON1 activity and MDA levels were analyzed in 37 patients with AMD and compared with 29 healthy controls using a spectrophotometric method. Serum MDA levels were significantly higher in the patient group (2.76 +/- 1.28 nmol/ml) than controls (1.00 +/- 0.36 nmol/ml; p < 0.001), whereas PON1 activity was lower in the patient group (132.27 +/- 63.39 U/I) than controls (312.13 +/- 136.23 U/I; p < 0.001). There was a negative correlation between MDA and PON1 levels (r = - 0.470, p < 0.001). We conclude that the observed increase in MDA levels may be related to decreased PON1 activity; the present data also demonstrated that an obvious negative correlation between PON1 activity and MDA levels exists in patients with AMD. PON1 is also an antioxidant agent, therefore effective antioxidant therapy to inhibit lipid peroxidation is necessary and agents to increase PON1 activity may be a therapeutic option in AMD. Copyright (c) 2006 S. Karger AG, Basel